Two Sigma Investments LP Boosts Stake in Savara Inc (NASDAQ:SVRA)

Two Sigma Investments LP grew its stake in shares of Savara Inc (NASDAQ:SVRA) by 19.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 785,477 shares of the company’s stock after buying an additional 127,628 shares during the quarter. Two Sigma Investments LP owned 0.46% of Savara worth $2,411,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Altium Capital Management LLC raised its position in shares of Savara by 0.3% during the 4th quarter. Altium Capital Management LLC now owns 1,579,000 shares of the company’s stock valued at $4,848,000 after buying an additional 4,000 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Savara by 14.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock valued at $112,000 after buying an additional 4,732 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Savara by 13.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 43,668 shares of the company’s stock valued at $135,000 after buying an additional 5,236 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Savara by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company’s stock valued at $441,000 after buying an additional 5,450 shares in the last quarter. Finally, Barclays PLC raised its position in shares of Savara by 2.5% during the 4th quarter. Barclays PLC now owns 236,705 shares of the company’s stock valued at $728,000 after buying an additional 5,700 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on SVRA shares. Wells Fargo & Company lowered their price objective on shares of Savara from $8.00 to $7.00 and set an “overweight” rating on the stock in a research report on Wednesday. Evercore ISI reduced their target price on shares of Savara from $3.00 to $2.00 and set an “in-line” rating on the stock in a report on Wednesday. Guggenheim reaffirmed a “buy” rating and set a $8.00 target price (down previously from $9.00) on shares of Savara in a report on Wednesday. Finally, HC Wainwright lowered shares of Savara from a “buy” rating to a “neutral” rating and reduced their target price for the company from $6.00 to $2.00 in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Savara currently has an average rating of “Moderate Buy” and a consensus price target of $7.17.

Savara Price Performance

SVRA stock opened at $2.29 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara Inc has a 52 week low of $1.89 and a 52 week high of $5.11. The firm’s fifty day moving average is $2.92 and its 200 day moving average is $2.94. The firm has a market cap of $395.80 million, a P/E ratio of -5.33 and a beta of 0.44.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). Research analysts predict that Savara Inc will post -0.45 earnings per share for the current year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.